Publicaciones (73) Publicaciones en las que ha participado algún/a investigador/a

2021

  1. A novel circulating microRNA for the detection of acute myocarditis

    New England Journal of Medicine, Vol. 384, Núm. 21, pp. 2014-2027

  2. A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer

    Breast Cancer Research, Vol. 23, Núm. 1

  3. A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer

    Future Oncology, Vol. 17, Núm. 30, pp. 3911-3924

  4. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

    Annals of Oncology, Vol. 32, Núm. 12, pp. 1571-1581

  5. Ansiedad y percepción de los estudiantes de Medicina en su rotación clínica en Obstetricia durante la pandemia por COVID-19

    Revista Española de Educación Médica, Vol. 2, Núm. 1, pp. 13-21

  6. Anthracyclines for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Are We Ready to Let Them Go?

    Journal of Clinical Oncology

  7. Anthracyclines strike back: Rediscovering non‐pegylated liposomal doxorubicin in current therapeutic scenarios of breast cancer

    Cancers, Vol. 13, Núm. 17

  8. Beta-blocker therapy in elderly patients with renal dysfunction and heart failure

    Journal of Geriatric Cardiology, Vol. 18, Núm. 1, pp. 20-29

  9. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

    Annals of Oncology, Vol. 32, Núm. 9, pp. 1148-1156

  10. CDK4/6 inhibitors in breast cancer: spotting the difference

    Nature Medicine

  11. Cardiac magnetic resonance in recovering COVID-19 patients. Feature tracking and mapping analysis to detect persistent myocardial involvement

    IJC Heart and Vasculature, Vol. 36

  12. Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial

    The Lancet Oncology, Vol. 22, Núm. 6, pp. 858-871

  13. Clinical Validation of a 3-Dimensional Ultrafast Cardiac Magnetic Resonance Protocol Including Single Breath-Hold 3-Dimensional Sequences

    JACC: Cardiovascular Imaging, Vol. 14, Núm. 9, pp. 1742-1754

  14. Clinical, pathological, and molecular features of breast carcinoma cutaneous metastasis

    Cancers, Vol. 13, Núm. 21

  15. Coexistence of transmural and lateral wavefront progression of myocardial infarction in the human heart

    Revista Espanola de Cardiologia, Vol. 74, Núm. 10, pp. 870-877

  16. Compassionate use of remdesivir in children with COVID-19

    European Journal of Pediatrics, Vol. 180, Núm. 4, pp. 1317-1322

  17. Concordant Sum of Cytology and Colposcopy Is Validated by Guidelines to Evaluate the Evolution of Low-Grade Lesions

    Journal of Lower Genital Tract Disease

  18. ERANET JTC 2011: Submission and Activation of an International Academic Translational Project in Advanced Breast Cancer. Experience From the ET-FES Study

    Frontiers in Medicine, Vol. 8

  19. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer ☆

    Annals of Oncology, Vol. 32, Núm. 12, pp. 1475-1495

  20. Efficacy and safety of intramuscular administration of allogeneic adipose tissue derived and expanded mesenchymal stromal cells in diabetic patients with critical limb ischemia with no possibility of revascularization: study protocol for a randomized controlled double-blind phase II clinical trial (The NOMA Trial)

    Trials, Vol. 22, Núm. 1